To hear about similar clinical trials, please enter your email below
Trial Title:
ALDH1A1 Expression in Invasive Mammary Carcinoma
NCT ID:
NCT06134570
Condition:
Breast Cancer
Conditions: Official terms:
Breast Neoplasms
Conditions: Keywords:
breast cancer
CSCs
ALDH1A1
Study type:
Observational
Overall status:
Enrolling by invitation
Study design:
Time perspective:
Retrospective
Summary:
ALDH1A1 isozyme oxidizes Retinaldehyde to retinoic acid, which regulates the expression
of the genes involved in tumor-initiating stem-like cells, thereby initiating tumor
growth and resistance to drugs.
Much emphasis has been focused on ALDH1A1 as a CSC marker. High expression of ALDH1A1 has
been reported as a poor prognostic marker in several tumor types and is associated with
poor patient outcomes .
Detailed description:
Breast cancer is one of the most common cancers among women. it is a heterogenous
disease. several factors affect the prognosis of breast cancer. CSCs markers are one of
the emerging prognostic biomarkers.
ALDH1A1 isozyme oxidizes Retinaldehyde to retinoic acid, which regulates the expression
of the genes involved in tumor-initiating stem-like cells, thereby initiating tumor
growth and resistance to drugs.
Much emphasis has been focused on ALDH1A1 as a CSC marker. High expression of ALDH1A1 has
been reported as a poor prognostic marker in several tumor types and is associated with
poor patient outcomes .
Criteria for eligibility:
Study pop:
sixty paraffin blocks of breast carcinoma collected from the archive of Pathology
Department of Sohag Faculty of Medicine
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
- Patients with invasive mammary carcinoma carcinoma and underwent surgery
Exclusion Criteria:
- Cases received pre-operative chemotherapy or radiotherapy.
- Cases with insufficient clinical data.
Gender:
Female
Minimum age:
N/A
Maximum age:
N/A
Locations:
Facility:
Name:
Faculty of Medicine
Address:
City:
Sohag
Country:
Egypt
Start date:
October 1, 2023
Completion date:
June 1, 2024
Lead sponsor:
Agency:
Sohag University
Agency class:
Other
Source:
Sohag University
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06134570
